NASDAQ:TNDM Tandem Diabetes Care (TNDM) Stock Price, News & Analysis $11.80 +0.75 (+6.76%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Tandem Diabetes Care Stock (NASDAQ:TNDM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tandem Diabetes Care alerts:Sign Up Key Stats Today's Range$11.16▼$12.0550-Day Range$10.11▼$20.7652-Week Range$9.98▼$47.60Volume410,594 shsAverage Volume1.72 million shsMarket Capitalization$797.12 millionP/E RatioN/ADividend YieldN/APrice Target$22.47Consensus RatingHold Company Overview Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Read More Tandem Diabetes Care Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreTNDM MarketRank™: Tandem Diabetes Care scored higher than 90% of companies evaluated by MarketBeat, and ranked 109th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingTandem Diabetes Care has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tandem Diabetes Care's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.68) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tandem Diabetes Care's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.20% of the float of Tandem Diabetes Care has been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Tandem Diabetes Care has recently decreased by 13.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-0.64 Percentage of Shares Shorted13.20% of the float of Tandem Diabetes Care has been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Tandem Diabetes Care has recently decreased by 13.37%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment1.03 News SentimentTandem Diabetes Care has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Tandem Diabetes Care this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have bought more of their company's stock than they have sold. Specifically, they have bought $251,711.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Tandem Diabetes Care is held by insiders.Read more about Tandem Diabetes Care's insider trading history. Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address TNDM Stock News HeadlinesCitigroup Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $11.00August 22 at 2:51 AM | americanbankingnews.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | tmcnet.comGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldman Sachs and JPMorgan forecasting as high as $6,000, now may be the most critical time in a generation to move.August 22 at 2:00 AM | Reagan Gold Group (Ad)Securities Fraud Investigation Into Tandem Diabetes Care, Inc. ...August 14, 2025 | gurufocus.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmAugust 14, 2025 | businesswire.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...August 14, 2025 | gurufocus.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | businesswire.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from AnalystsAugust 14, 2025 | americanbankingnews.comSee More Headlines TNDM Stock Analysis - Frequently Asked Questions How have TNDM shares performed this year? Tandem Diabetes Care's stock was trading at $36.02 at the beginning of 2025. Since then, TNDM stock has decreased by 69.3% and is now trading at $11.05. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, August, 6th. The medical device company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.08. The business's revenue for the quarter was up 8.5% on a year-over-year basis. Read the conference call transcript. When did Tandem Diabetes Care's stock split? Shares of Tandem Diabetes Care reverse split on Tuesday, October 10th 2017.The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's top institutional investors include Hood River Capital Management LLC (3.80%), Paradice Investment Management LLC (2.62%), Stephens Investment Management Group LLC (2.61%) and Jennison Associates LLC (2.49%). Insiders that own company stock include Kim D Blickenstaff, John F Sheridan, Leigh Vosseller, Dick Allen, Jean-Claude Kyrillos, Kathleen Mcgroddy-Goetz, David B Berger, Shannon Marie Hansen and Mark David Novara. View institutional ownership trends. How do I buy shares of Tandem Diabetes Care? Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tandem Diabetes Care investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings8/06/2025Today8/22/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TNDM CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,650Year Founded2006Price Target and Rating Average Price Target for Tandem Diabetes Care$22.47 High Price Target$51.00 Low Price Target$11.00 Potential Upside/Downside+103.3%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.03 million Net Margins-20.51% Pretax Margin-20.21% Return on Equity-65.40% Return on Assets-13.87% Debt Debt-to-Equity Ratio2.32 Current Ratio2.44 Quick Ratio1.88 Sales & Book Value Annual Sales$940.20 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book5.61Miscellaneous Outstanding Shares67,570,000Free Float66,285,000Market Cap$746.65 million OptionableOptionable Beta1.46 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:TNDM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tandem Diabetes Care With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.